Vermont, Public Health “Emergencies,” And Vaccines (THE PREP ACT)

Publisher’s Note: As champions here in Vermont’s Green Mountains of health freedom and informed consent, we’ve covered the public discussion around vaccines for several years. Given the current COVID craziness, we’re opening up a thread on mandatory vaccinations in the Age of the Coronavirus. Below, find Spiro in conversation with vaccine researcher and osteopathic physician Dr. Sherry Tenpenny discussing our COVID moment, and the U.S. Health And Human Services “Public Readiness And Emergency Preparedness” (PREP) ACT, which indemnifies the pharmaceuticals industry from the health consequences of vaccines during a ” public health emergency” as declared by the US HHS. Screen shot, and TenPenny video interview below. Meanwhile, 29-year-old Seattle’ite Ian Haydon weighs in with StatNews about his experience as one of the first volunteer human test subject participants for Moderna Therapeutics’ clinical trials of a new and untested coronavirus vaccine. Full transcript of the article below, along with Children’s health Defense spokesperson Robert F. Kennedy’s Instagram commentary. Eye opening. Finally, Ellen Brown eight in on the politics and profit motive behind a COVID-19 vaccine.

In this explosive interview above, Spiro Skouras is joined by Dr. Sherri Tenpenny. The two discuss the latest developments regarding the coronavirus situation which was declared a global health pandemic, by the Gates funded World Health Organization, as more information comes to light questioning the need for a global lockdown. Dr. Tenpenny and Spiro examine and explore, the motives of the global response by governments, global institutions and private interests, as Dr. Tenpenny exposes perhaps the most alarming aspect of the crisis yet! No, it is not the virus, it is the blank check issued to the vaccine and drug manufacturers, which not only provides unlimited funding, but also provides blanket immunity to Big Pharma for any harm attributed with the treatments produced during the declared emergency, including all drugs and vaccines. This blanket immunity is provided by the US government under the PREP Act and provides the drug and vaccine manufacturers the ‘Ultimate Blank Check’ during a declared emergency. As Dr. Tenpenny points out, the vaccine and drug manufacturers have zero incentive to produce a safe product, as the declared emergency not only rolls back regulatory standards and removes them from any and all liability, but it also ensures the government will purchase their products. This is an unprecedented level of immunity which raises many questions and safety concerns.

From STAT NEWS:

Patients in clinical trials are usually faceless. But as the experimental Covid-19 vaccine being developed by Moderna Therapeutics has begun advancing through studies, it has found a much more visible advocate: trial volunteer Ian Haydon, a 29-year-old in Seattle.

Haydon has spoken about the vaccine on CNN and CNBC. He even said he’d volunteer to be exposed to the novel coronavirus, SARS-CoV-2, if researchers want to test to see if the vaccine was actually effective. But up until now he has left out a key detail: He is, apparently, one of three people in the trial who had a systemic adverse reaction to the vaccine. 

Twelve hours after receiving his second dose, he developed a fever of more than 103 degrees, sought medical attention, and, after being released from an urgent care facility, fainted in his home. He recovered within a day.

He has not brought up the side effects previously, he said, out of “an abundance of caution.”

“I understand that sharing the story, it’s going to be frightening to some people,” he said. “I hope that it doesn’t fuel any sort of general antagonism towards vaccines in general or towards even this vaccine.”

But he decided to speak now because he hopes his story counterbalances the desperation that some people feel to push a vaccine to market regardless of the consequences. Haydon points out that the whole purpose of the study he was in, known as a Phase 1 clinical trial, is to find the right dose of the vaccine going forward. That means to find a dose that causes the body to produce antibodies, but does not result in too many side effects.

“As we rush to get a vaccine developed as quickly as possible, the reality of vaccine development is that it can only be rushed so much and the trial still needs to take place,” Haydon said. “They have to move at the speed they move at. And stories like what happened to me, they matter because they shape the approval process.”

In the 45-person Moderna study, four participants experienced what are known as “Grade 3” adverse events — side effects that are severe or medically significant but not immediately life-threatening. Neither the company nor the National Institute of Allergy and Infectious Diseases, which is running the trial, have previously detailed the nature of those incidents, but Moderna did disclose that three, likely including Haydon, received the highest dose of the vaccine that was tested, and had reactions that involved their whole bodies. A fourth received a lower dose and had a rash at the injection site. 

Such side effects are “noteworthy, but it doesn’t stop the train,” said William Schaffner, a professor of preventive medicine and infectious diseases at Vanderbilt University Medical Center. The goal of studies is to establish a threshold at which something might go wrong. 

With drugs, Schaffner said, patients tolerate the risk of side effects because they want to get better. “In contrast,” Schaffner said, “we give vaccines to healthy people in anticipation that they might contact the germ, the virus, down the road. But because we give them to healthy people, actually our standards for safety are higher than they are for drugs.” 

In Haydon’s words: “The point of the Phase 1 trial is to look out for health problems.” He said he received great medical care, and though he felt more sick than he ever has before, he was never afraid for his long-term health. “I don’t regret the decision I made to enroll in this study.”

Haydon, a communications manager at a university, initially found out about the study, which was being run in Seattle, from a colleague who sent him a link. He, along with thousands of other people, applied. They called him 11 days after he applied. 

He went to the trial site for a physical, and signed a 20-page consent form. The vaccine, it told him, could conceivably cause severe anaphylactic shock, and there was no way to predict exactly how his immune system would respond to the new vaccine. He’d looked at research on other Moderna experimental vaccines, which work via an entirely new technology that uses messenger RNA, the body’s key envoy of genetic information inside cells, and thought they seemed relatively safe. During the physical, researchers took blood; the lab work came back a week later, and he received his first dose of the vaccine on April 8.

Haydon doesn’t like needles, and was as worried about the blood draw — which uses a bigger needle — than the actual shot. He remembers waiting, and being told that the reason he was waiting was because researchers were giving doses in ascending order, and he was to receive the high dose of the vaccine. But the injection was uneventful. If his eyes were closed, he said, he would not have felt it. He was given a paper log on which to write down any symptoms, a digital thermometer, and a small ruler to measure any reactions at the injection site. 

He had arm pain the next day, “like being punched in the arm,” he said, and for a day he had trouble lifting his arm at the shoulder. But within days he was back to normal.

Haydon said he was slightly nervous before the second dose. He knew that second doses were given to increase the immune system’s response, and wondered if he might have more side effects. His arm became sore much more quickly this time. He got home from the clinic at about noon. At around 10 p.m., he started to get chills. He’s normally too hot at night, but he bundled up in sweats. His fingertips felt cold. He fell asleep, but woke up a few hours later with a raging fever.

At 1:30 a.m., his temperature was 103.2 degrees. At 3:45, it was 103 degrees. He was nauseous, and his muscles hurt. 

The clinic where he was vaccinated had given him a 24-hour phone number to call, but he’d been reticent. His girlfriend, with whom he lives, called. They said to go to urgent care. It was a 10-minute drive. They arrived at 5 a.m.

The doctors met him in what looked like space suits. Even though he’d had a vaccine, he was also a potential Covid patient. They took him into an exam room, took a lot of blood, and gave him a nasal swab. He asked them to avoid his left arm, where he’d gotten the vaccine, but they ended up taking blood from both of his arms. His fever had already fallen to 99.8 degrees. They gave him Tylenol. The physician taking care of him offered to try to get him admitted to a neighboring hospital, but he decided to head home.

He and his girlfriend arrived home at 7 a.m., and he slept until noon. His temperature was 101.5. He got up to go to the bathroom, and became so nauseous he threw up. On his way back from the bathroom, he fainted. His girlfriend caught him and kept his head from hitting the floor. 

She then called one of the doctors working in the study, and asked what they should do. The doctor told them he could go back to urgent care, or call 911, and reminded them that all his medical costs would be covered by the study.

But he got to a couch and was given sports drinks. He spent the afternoon there, with a wet towel on his head, fighting the fever. By 9:45 p.m., it was back down to 99.1. It tapered off. He says he felt better within a few days, and has had no side effects since. 

Haydon said the experience left him as sick as he’d ever felt. But standard flu-like symptoms that resolve within a day are not necessarily considered a reason not to use a vaccine that prevents a more serious illness. 

Given the stakes of a Covid-19 vaccine, the side effects described in the Moderna release would likely be seen as acceptable even if they turned out to be seen in future studies. The severe effects were only seen at high doses that are not being taken forward. The other vaccine for which early data are available caused fever in almost half of recipients.

But it’s also not clear what will happen as the vaccine moves into larger studies. “Humans have a very diverse immune system,” said Larry Schlesinger, the president and CEO of the Texas Biomedical Research Institute, a nonprofit. “And then you add on top of that diabetes or, you know, age 70 and you can imagine that the immune response will be very, very different.”

The difficulty, Schlesinger said, is that right now we are only getting “tidbits” of information about the new vaccine. 

“Tidbits of science are always dangerous for the public to read because they give a false understanding, or a false sense of security, that we’re making progress or not,” Schlesinger said. “And then tomorrow we hear something completely opposite. And before you know it, the credibility of the scientific process is undermined and people stop listening.”

What does he think now? “It’s just not enough information at the current time.” That’s why we need clinical trials — and volunteers like Ian Haydon.

And RFK Jr from his Instagram:

You know Ian Haydon from many appearances on CNN and other networks celebrating his heroic act of volunteering to test Moderna’s experimental Covid vaccine. The sun has now set on Haydon’s television career. He is no longer useful to the Pharmedia narratives that all vaccines are always safe for all people,that Moderna’s business partners,Tony Fauci and Bill Gates we’re justified in skipping animal studies and that Moderna’s vaccine will soon rescue us from the Pandemic. Ian Haydon is now an embarrassment to Fauci & Gates and their CNN cheerleaders. He will therefore vanish into the censorship twilight. Moderna chose Haydon for the study because of his robust good health. He was among the 15 volunteers in the high dose group. Within 45 days ,three of these-a shocking 20% -experienced “serious” adverse events according to Moderna’s press release meaning they required hospitalization or medical intervention. Less than 12 hours after vaccination, Hayden suffered muscle aches,vomiting,spiked a 103.2*fever and lost consciousness. His girlfriend caught him as he fell. His Moderna trial supervisor instructed Haydon to call 911 and described him as being the “sickest in his life”. Moderna let Haydon believe the illness was just a sad coincidence unrelated to the jab. Moderna never told Haydon he was suffering an Adverse Event. “Moderna’s press release was the first I learned of the 3 AEs in the high dose group.”Haydon confessed today on Twitter,”Later a study doc confirmed that what happened to me was an AE.” While hiding this truth,Moderna encouraged Haydon to appear on tv to deceive the public and it’s shareholders by declaring Moderna’s COVID vaccine trials a smashing success. On May 7 Haydon told Sanjay Gupta about his reactions in a pre interview. The two men agreed to keep this bad news secret when he went on air. This corrupt deal bespeaks the pathetic state of journalism at CNN. Fauci and Gates are proceeding with their plan to funnel half a billion taxpayer dollars into their reckless vanity project to create 30 million doses by November and 2 billion within a year manufactured in the US and Switzerland.

SNIP – and here’s Ellen Brown:

When Profits and Politics Drive Science: 

Rushing a Vaccine to Market for a Vanishing Virus

Ellen Brown

June 4, 2020

More than 100 companies are competing to be first in the race to get a COVID-19 vaccine to market. It’s a race against time, not because the death rate is climbing but because it is falling – to the point where there will soon be too few subjects to prove the effectiveness of the drug. 

Pascal Soriot is chief executive of AstraZeneca, a British-Swedish pharmaceutical company that is challenging biotech company Moderna, the U.S. frontrunner in the race. Soriot said on May 24^th, “The vaccine has to work and that’s one question, and the other question is, even if it works, we have to be able to demonstrate it. We have to run as fast as possible before the disease disappears so we can demonstrate that the vaccine is effective.”

COVID-19, like other coronaviruses, is expected to mutate at least every season, raising serious questions about claims that any vaccine will work. A successful vaccine has never been developed for any of the many strains of coronaviruses, due to the nature of the virus itself; and vaccinated people can have a higher chance of serious illness and death when later exposed to another strain of the virus, a phenomenon known as “virus interference.” An earlier SARS vaccine never made it to market because the laboratory animals it was tested on contracted more serious symptoms on re-infection, and most of them died. 

Researchers working with the AstraZeneca vaccine claimed success in preliminary studies because its lab monkeys all survived and formed antibodies to the virus, but data reported later showed that the animals all became infected when challenged, raising serious questions about the vaccine’s effectiveness. 

Moderna has gotten fast-track approval from the FDA and managed to skip animal trials altogether before rushing to human trials. Its candidate is a “messenger RNA” vaccine, a computer-generated replica of an RNA component that carries genetic information controlling the synthesis of proteins. No mRNA vaccine has ever been approved for marketing or proven in a large-scale clinical trial. As explained in Science Magazine, RNA that invades from outside the cell is the hallmark of a virus, and our immune systems have evolved ways to recognize and destroy it. To avoid that, Moderna’s mRNA vaccine sneaks into cells encapsulated in nanoparticles, which aren’t easily degraded and can cause toxic buildup in the liver.

These concerns, however, have not deterred the U.S. Department of Health and Human Services (HHS), which is proceeding at “Warp Speed” to get the new technologies tested on the American population before the virus disappears through mutation and natural herd immunity. HHS has already agreed to provide up to $1.2 billion to AstraZeneca and $483 million to Moderna to develop their experimental candidates. “As American taxpayers, we are justified in asking why,” writes William Haseltine in Forbes. Both companies have attracted billions from private investors and don’t need taxpayer money, and the government’s speculative bets are being made on unproven technologies in the early stages of testing. 

The argument at one time was that the magnitude of the crisis justified the risk, but the virus is now disappearing of its own accord. The computer-modeled projection of 2.2 million U.S. deaths issued by Imperial College London (a business partner of AstraZeneca), triggering shutdowns across the United States, was subsequently found to be “wildly” overblown. The model was described in the UK Telegraph on May 16^th as “the most devastating software mistake of all time.” The researchers wrote that “we would fire anyone for developing code like this” and that the question was “why our Government did not get a second opinion before swallowing Imperial’s prescription.”   

The U.S. Centers for Disease Control has also revised its projections. Experts disagree on what the new data means, but according to an expert at the Montreal Economic Institute, “The most likely CDC scenario now estimates that the coronavirus mortality rate for infected people is between 0.2% and 0.3%. This is a far cry from the 3.4% figure that had been put forward by the WHO at the start of the pandemic.”

In other news from the CDC, on May 23^rd the agency reported that the antibody tests used to determine whether people have developed an immunity to the virus are too unreliable to be used. 

But none of this seems to be dimming the hype and the deluge of investment money being thrown at the latest experimental vaccines. And perhaps that is the point of the exercise – to extract as much money as possible from gullible investors, including the US government, before the public discovers that the fundamentals of these stocks do not support the media hype. 

Moderna: A Multibillion-Dollar “Unicorn” That Has Never Brought a Product to Market

Moderna in particular has been suspected of pumping its stock price with unreliable preliminary test data. On May 18^th, Moderna’s stock jumped by as much as 30%, after it issued a press release announcing positive results from a small preliminary trial of its coronavirus vaccine. After the market closed, the company announced a stock offering aimed at raising $1 billion; and on May 18^th and 19^th, Moderna executives dumped nearly $30 million worth of stock for a profit of $25 million.  

On May 19^th, however, the stock rocketed back down, after STAT News questioned the company’s test results. An antibody response was reported for only eight of the 45 patients, not enough for statistical analysis. Was the response significant enough to create immunity? And what about the other 37 patients?

Robert F. Kennedy Jr. called the results a “catastrophe” for the company. He wrote on May 20^th:

Three of the 15 human guinea pigs in the high dose cohort (250 mcg) suffered a “serious adverse event” within 43 days of receiving Moderna’s jab. Moderna … acknowledged that three volunteers developed Grade 3 systemic events, defined by the FDA as “Preventing daily activity and requiring medical intervention.” 

Moderna allowed only exceptionally healthy volunteers to participate in the study. A vaccine with those reaction rates could cause grave injuries in 1.5 billion humans if administered to “every person on earth”.

A volunteer named Ian Haydon buoyed the markets when he appeared on CNBC to say he felt fine after getting the vaccine. But he later revealed that after the second jab, he got chills and a fever of over 103°, lost consciousness, and “felt more sick than he ever has before.”  

Those were just the short-term adverse effects. Long-term systemic effects including cancer, Alzheimer’s disease, autoimmune disease, and infertility can take decades to develop. But the stage is already being set for mandatory vaccinations that will be “deployed” by the U.S. military as soon as the end of the year. The HHS in conjunction with the Department of Defense has awarded a $138 million contract for 600

million syringes prefilled with coronavirus vaccine, individually marked with trackable RFID chips. That’s enough for two doses for nearly the entire U.S. population. One hundred million are to be supplied by year’s end. 

Fortunately for vaccine manufacturers and investors, they do not have to worry about the drugs’ side effects, since the National Vaccine Injury Compensation Program and the 2005 PREP Act protect them from liability for vaccine injuries. Damages are imposed instead on the US government and US taxpayers. 

What Moderna could have to worry about, however, is criminal action by the Securities Exchange Commission. By May 22^nd, Moderna’s stock was down by 26% from its earlier high, making its 30% rise on a misleading press release look like a “pump and dump” scheme. On CNBC on May 19^th, former SEC lawyer Jacob Frankel said its stock offering on the heels of hyped news was the type of action that would draw scrutiny by the SEC, and that it could have a criminal component.

Why All the Hype? Moderna’s mRNA Vaccine

It wasn’t the first time Moderna’s stock had skyrocketed on a well-timed press release. On February 24^th, the World Health Organization said to prepare for a global pandemic, collapsing stock markets around the world. Most stocks collapsed, but Moderna’s shot up by nearly 30%, after it reported on February 25^th that testing on humans would begin in March. Mega-investors made tens of millions of dollars in a single day, including BlackRock, the world’s largest asset manager, which made $68 million just on February 25^th. BlackRock was called “the fourth branch of government” after it was tasked in March with dispensing up to $4.5 trillion in Federal Reserve credit through “special purpose vehicles” established by the Treasury and the Fed. 

Moderna has other friends in high places, including the Pentagon. Several years ago, Moderna received millions of dollars from the Pentagon’s Defense Advanced Research Projects Agency (DARPA), as well as from the Bill and Melinda Gates Foundation. Moderna’s stock has more than tripled this year, taking it to a market cap of over $22 billion. STAT News called it “an astonishing feat for a company that currently sells zero products.” Many of the companies actively developing COVID-19 vaccines have longer and more impressive track records. Why all the investor interest in this “unicorn” startup that went public only in 2018 and has no record of market success?  

The major advantage of mRNA vaccines is the speed with which they can be deployed. Created in a lab rather than from a real virus, they can be mass-produced cost-effectively on a large scale and do not require uninterrupted cold storage. But this speed comes at the risk of major side effects. In a 2017 TED talk called “Rewriting the Genetic Code,” Moderna’s current chief medical officer Dr. Tal Zaks said, “We’re actually hacking the software of life ….” 

As explained by a medical doctor writing in The UK Independent on May 20^th:

Moderna’s messenger RNA vaccine … uses a sequence of genetic RNA material produced in a lab that, when injected into your body, must invade your cells and hijack your cells’ protein-making machinery called ribosomes to produce the viral components that subsequently train your immune system to fight the virus. …

In many ways, the vaccine almost behaves like an RNA virus itself except that it hijacks your cells to produce the parts of the virus, like the spike protein, rather than the whole virus. Some messenger RNA vaccines are even self-amplifying…. There are unique and unknown risks to messenger RNA vaccines, including the possibility that they generate strong type I interferon responses that could lead to inflammation and autoimmune conditions.

A lab-created self-amplifying virus encapsulated in nanoparticles that evade the cell’s defenses by stealth sounds a lot like the “stealth viruses” that are classified as “bioweapons,” and that could explain DARPA’s interest in the technology. In a 2010 document titled “Biotechnology: Genetically Engineered Pathogens,” the US Air Force acknowledged that it was studying “genetically engineered pathogens that could pose serious threats to society,” including “binary biological weapons, designer genes, gene therapy as a weapon, stealth viruses, host-swapping diseases, and designer diseases.” DARPA was behind the creation of both DNA and RNA vaccines, funding their early research and development by Moderna as well as by Inovio Pharmaceuticals Inc. 

In December 2017, over 1,200 emails released under open records requests revealed that the U.S. military is now the top funderbehind the controversial “genetic extinction” technology known as “gene drives.” As investigative reporter Whitney Webb observed in a May 4^th article, “these genetic ‘kill switches’ could also be inserted into actual humans through artificial chromosomes, which – just as they have the potential to extend life – also have the potential to cut it short.” Biowarfare is forbidden under international treaty, but the army’s Medical Research Institute of Infectious Diseases at Fort Detrick says its investigations are to “protect the warfighter from biological threats” and to protect civilians from threats to public health. Even assuming that is true, are the army’s technicians proficient enough to tinker with the human genetic code without hitting a kill switch or two by mistake?

The military is thinking about war, the pharmaceutical companies and investors are thinking about profits, the politicians are thinking about getting the country back to work, and even the regulators are bypassing proper safety tests in the rush to get the entire global population vaccinated before the virus disappears. It is left to us, the recipients of these novel untested GMO vaccines, to demand some serious vetting before the military shows up at our doors with their prefilled RFID-chipped syringes some time later this year. 

________________________

Ellen Brown is an attorney, chair of the Public Banking Institute, and author of thirteen books including Web of Debt, The Public Bank Solution, and Banking on the People: Democratizing Money in the Digital Age.  She also co-hosts a radio program on PRN.FM called “It’s Our Money.” Her 300+ blog articles are posted at EllenBrown.com.